Home | Drug Target Review

Skip to main content
Skip to navigation

Featured content

From fragments to maps: scaling drug–target interaction data

2026-04-01T15:37:00+01:00By Drug Target Review

Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery.

Interview
Computational design drives new generation of synthetic promoters
2026-03-26T14:21:00+00:00By Drug Target Review
Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.
Interview
Physics-based modelling offers a new way to study drug targets
2026-03-26T14:15:00+00:00By Drug Target Review
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.
Article
Anticipating adaptation: understanding and overcoming cancer drug resistance
2026-03-26T13:58:00+00:00By Neil Bhowmick
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.

Opinion and interviews

Computational design drives new generation of synthetic promoters

2026-03-26T14:21:00+00:00By Drug Target Review

Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.

Opinion and interviews

Previous
Next

Webinars

Previous
Next

Whitepapers

Previous
Next